Clinical trials: Chronic Kidney Disease - Stage V
COVID-19, Chronic Kidney Disease stage4
Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
Nirmatrelvir-ritonavir is approved for coronavirus disease 2019 (COVID-19) but not initially recommended in patients with severe renal impairment.
- Conditions
- COVID-19, Chronic Kidney Disease stage4, Chronc Kidney Disease Stage 5
- Trial name
- NCT05624840
- Testing
- Nirmatrelvir/ritonavir
- Where
- Hong Kong
- Volunteers
- 85 people
- Sponsor
- Chinese University of Hong Kong
Chronic Kidney Disease, Stage 5, Chronic Kidney Disease, Stage 4
A Cohort Study on the Integrated Management of Chronic Kidney Disease
The study will leverage the established multi-stage cohort resources at Huashan Hospital, covering the entire spectrum from early-stage CKD to dialysis, including a comorbidity real-world database, a prospective CKD patient…
- Conditions
- Chronic Kidney Disease, Stage 5, Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 3
- Trial name
- NCT07712341
- Testing
- Retrospective data collection, Prospective data collection, External validation
- Where
- China
- Volunteers
- 4,029 people
- Sponsor
- Huashan Hospital
Chronic Kidney Disease
Patient INformation About Options for Treatment - PINOT
This prospective observational study is designed to find out what treatment options new patients with chronic kidney disease learn about from their renal unit.
- Trial name
- PINOT (NCT01298115)
- Where
- Australia
- Volunteers
- 721 people
- Sponsor
- University of Sydney
Anemia
An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)
This observational study will evaluate the use and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in anemia patients with chronic kidney disease (CKD) stage III-IV not on dialysis or CKD stage V on dialysis.
- Trial name
- NCT01667380
- Where
- Montenegro
- Volunteers
- 78 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
This is a descriptive single arm open-label interventional trial lasting 6 weeks aiming to test if a low protein healthy K-rich diet with fruits, vegetables, whole grains, and nuts with concomitant use of new potassium binder…
- Conditions
- Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Hyperkalemia
- Trial name
- HELPFUL (NCT04207203)
- Testing
- sodium zirconium cyclosilicate and healthy diet
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Karolinska Institutet
Anemia
A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)
This retrospective observational study will assess the incidence of hemoglobin cycling in chronic kidney disease (stage 3, 4, and 5) patients with renal anemia treated with Mircera (methoxy polyethylene glycol-epoetin beta).
- Trial name
- NCT01356589
- Where
- 33 sites in Greece
- Volunteers
- 1,288 people
- Sponsor
- Hoffmann-La Roche
FSGS
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
- Trial name
- NCT02683889
- Testing
- Acthar
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Colorado, Denver
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
- Trial name
- NCT03602261
- Testing
- Calcifediol Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Dyslipidemia
- Trial name
- NCT00542386
- Testing
- MCI-196
- Where
- 73 sites in Hungary, Italy and 6 more
- Volunteers
- 642 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
To evaluate the effects of paricalcitol injection on cardiac structure and function over 48 weeks in subjects with Stage 5 Chronic Kidney Disease (CKD) receiving hemodialysis who have left ventricular hypertrophy (LVH).
- Trial name
- PRIMO II (NCT00616902)
- Testing
- paricalcitol injection 4 mcg/mL
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 12 people
- Sponsor
- Abbott
Hyperphosphatemia, Kidney Disease
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney.
- Trial name
- NCT00660530
- Testing
- Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Illinois Chicago
End-Stage Kidney Disease
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to…
- Trial name
- NCT00062699
- Testing
- Zemplar (paricalcitol injection), Calcijex
- Where
- 60 sites in United States
- Volunteers
- 2,200 people
- Sponsor
- Abbott
Chronic Kidney Disease Stage 5, Periodontitis
Effect of Non-surgical Periodontal Treatment and C-reactive Protein Levels in Hemodialysis Patients
The presence of periodontitis has been hypothesized as a risk factor for several systemic outcomes, including chronic kidney disease (CKD).
- Trial name
- NCT04262011
- Testing
- immediate treatment, postponed treatment
- Where
- Brazil
- Volunteers
- 88 people
- Sponsor
- Universidade Federal de Santa Maria
Hypoalbuminemia, Protein-energy Malnutrition
Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
Study of efficiency and safety of oral nutritional supplements with anti-inflammatory and antioxidative properties combined with an appetite stimulant with anti-inflammatory properties (pentoxiphylline) in treatment of…
- Conditions
- Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress
- Trial name
- AIONID (NCT00561093)
- Testing
- pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa)
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)
Open-label, pharmacodynamic, safety, pharmacokinetic and efficacy study of Lunacalcipol Injection.
- Conditions
- Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT), Hemodialysis (HD)
- Trial name
- 2007 (NCT01453634)
- Testing
- Lunacalcipol 180, Lunicalcipol 270
- Sponsor
- OPKO Health, Inc.
Secondary Hyperparathyroidism
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic…
- Trial name
- NCT00463021
- Testing
- Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Stage 5 Chronic Kidney Disease
Impact of a Multidisciplinary Intensive Management Clinic on Outcomes in Multi-Ethnic Asian Incident Hemodialysis Patients
Patients with end-stage renal disease are most vulnerable in the early months following hemodialysis (HD) initiation. Data from the United States Renal Data System and Singapore Renal Registry showed high mortality rates in the…
- Trial name
- NCT01509690
- Testing
- Multidisciplinary, intensive and collaborative care
- Where
- Singapore
- Volunteers
- 150 people
- Sponsor
- National University of Singapore
Chronic Kidney Diseases, Atrial Fibrillation
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment.
- Conditions
- Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage
- Trial name
- SACK (NCT05679024)
- Testing
- Apixaban 2.5 milligram Oral Tablet
- Where
- 34 sites in Finland, Iceland and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Region Stockholm
Myocardial Fibrosis, End Stage Renal Failure on Dialysis
MRI Assessment of Myocardial Fibrosis Associated With Monocyte Phenotype in End Stage Renal Failure
Firstly, this study aims to understand how cardiac fibrosis mediated by inflammatory microvascular disease evolves during advanced chronic kidney disease and end stage renal failure and importantly how this changes with…
- Conditions
- Myocardial Fibrosis, End Stage Renal Failure on Dialysis, Chronic Kidney Disease, Stage IV (Severe), Chronic Kidney Disease Stage V
- Trial name
- CM3 (NCT03857633)
- Testing
- Cardiac MRI 1 - With Gadolinium Contrast, Cardiac MRI 2 - With Gadolinium Contrast, Cardiac MRI 3 - Without Gadolinium Contrast
- Where
- United Kingdom
- Sponsor
- Imperial College London
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)